Form 4 for CRL Charles River Laboratories
Accepted 2025-05-23 00:00:00 ET · period of report 2025-05-21 · accession 0001127602-25-015469 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-23 | 2025-05-21 | CRL | Andrews Nancy C | Dir | A - Grant | $134.98 | +946 | 3,964 | +31% | +$127.7K |
| D | 2025-05-23 | 2025-05-21 | CRL | Andrews Nancy C | Dir | A - Grant | $134.98 | +2,076 | 2,076 | New | +$280.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-21 | A | A | 946 | $134.98 | 3,964 | D | — | — | (F1) The unvested restricted stock units vest upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders. |
| 2 | Derivative | Stock Options (Right to Buy) | 2025-05-21 | A | A | 2,076 | $134.98 | 2,076 | D | $134.98 · 2026-05-21 to 2035-05-21 | 2,076 Common Stock | (F2) The stock options become exercisable upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders. |